Danny Liu

Invitation to participate in a survey on the organization and techniques of ATMP facilities by DARE-NL, EBMT, T2EVOLVE, and NXTGEN-HIGHTECH – a GoCART Coalition initiative

Dear GoCART stakeholder, We are reaching out to invite you to participate in a survey on the organization and techniques employed in Advanced Therapy Medicinal Product (ATMP) facilities across Europe

Invitation to participate in a survey on the organization and techniques of ATMP facilities by DARE-NL, EBMT, T2EVOLVE, and NXTGEN-HIGHTECH – a GoCART Coalition initiative Read More »

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CART) therapy

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement Read More »